The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics introduced the PTEN IHC CDx test as part of its PanTracer Pro offering. Shares edge higher on the day, trading at $17.46.
PTEN IHC CDx is now available as part of PanTracer Pro. The test combines IHC-based PTEN deficiency identification with comprehensive genomic profiling for a more complete biomarker picture. The announcement comes directly from the company.
View post on X Loading...
Stoch RSI is in oversold territory, a stretched reading that limits room for further downside. The chart shows that shares of NeoGenomics are holding above the Ichimoku Kijun at $17.33. Price remains above MA-20, MA-50, and MA-200, sustaining the broader bullish daily structure.
A close above $18.66 would show buyers are willing to follow through, while a drop below $17.33 would show the move is being faded. Price action shows Stoch RSI remains firmly oversold, with limited room below. Even so, over the next five trading days, the probability of upside is more than 80% and downside less than 20%, with an expected range of $16.73 to $18.18. On the weekly chart the longer-term picture stays constructive.
Previously it was reported that NeoGenomics maintained a bullish technical structure supported by FDA approval for its PTEN IHC CDx. With the PanTracer Pro launch now broadening utility for the test and shares holding key technical levels, focus turns to whether a sustained break above $18.66 can catalyze further upside momentum in the short term.